Alnuctamab for Refractory SLE (LATTE Study)

NCT07219563 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Alnuctamab

Sponsor

Icahn School of Medicine at Mount Sinai